RU2016112266A - Ингибитор PI3K для лечения респираторного заболевания - Google Patents
Ингибитор PI3K для лечения респираторного заболевания Download PDFInfo
- Publication number
- RU2016112266A RU2016112266A RU2016112266A RU2016112266A RU2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- use according
- infection
- respiratory
- patient
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 206010057190 Respiratory tract infections Diseases 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- NLUPPCTVKHDVIQ-GASCZTMLSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-GASCZTMLSA-N 0.000 claims 2
- 208000037920 primary disease Diseases 0.000 claims 2
- -1 1H-indol-4-yl Chemical group 0.000 claims 1
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (27)
1. Соединение формулы (I)
где
R1 представляет собой
R2 представляет собой
R1 представляет собой
R2 представляет собой
или его фармацевтически приемлемая соль для применения в лечении или предупреждении респираторной инфекции, лечении поражения дыхательных путей и/или предупреждении повреждения дыхательных путей у пациента.
2. Соединение для применения по п. 1, представляющее собой
6-(1Н-индол-4-ил)-4-(5-{[4-(1-метилэтил)-1-пиперазинил]метил}-1,3-оксазол-2-ил)-1H-индазол, или его фармацевтически приемлемая соль.
3. Соединение для применения по п. 1, представляющее собой
N-[5-[4-(5-{[(2R,6S)-2,6-диметил-4-морфолинил]метил}-1,3-оксазол-2-ил)-1Н-индазол-6-ил]-2-(метилокси)-3-пиридинил]метансульфонамид,
или его фармацевтически приемлемая соль.
4. Соединение для применения по п. 1 или 2, представляющее собой гемисукцинат 6-(1Н-индол-4-ил)-4-(5-{[4-(1-метилэтил)-1-пиперазинил]метил}-1,3-оксазол-2-ил)-1Н-индазола.
5. Соединение для применения по п. 1 или 3, представляющее собой N-[5-[4-(5-{[(2R,6S)-2,6-диметил-4-морфолинил]метил}-1,3-оксазол-2-ил)-1Н-индазол-6-ил]-2-(метилокси)-3-пиридинил]метансульфонамид.
6. Соединение для применения по п. 1, где применение представляет собой лечение или предупреждение респираторной инфекции.
7. Соединение для применения по п. 6, где респираторная инфекция представляет собой бактериальную инфекцию.
8. Соединение для применения по п. 7, где бактериальная инфекция представляет собой инфекцию S. pneumoniae, Н. influenzae и/или М. catarrhalis.
9. Соединение для применения по п. 7 или 8, где бактериальная инфекция представляет собой ринит, синусит, ларингит, бронхит, бронхиолит, тонзиллит, пневмонию и/или туберкулез.
10. Соединение для применения по п. 1, где пациент имеет первичное расстройство.
11. Соединение для применения по п. 10, где первичное расстройство представляет собой хроническую обструктивную болезнь легких (COPD).
12. Применение соединения по любому из пп. 1-5 или его фармацевтически приемлемой соли для изготовления лекарственного средства для использования в лечении или предупреждении респираторной инфекции, лечении поражения дыхательных путей и/или предупреждении повреждения дыхательных путей у пациента.
13. Способ лечения или предупреждения респираторной инфекции, лечения поражения дыхательных путей и/или предупреждения повреждения дыхательных путей у пациента, включающий введение безопасного и эффективного количества соединения по любому из пп. 1-5 или его фармацевтически приемлемой соли пациенту, нуждающемуся в этом.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201318415A GB201318415D0 (en) | 2013-10-17 | 2013-10-17 | Novel use |
GB1318415.5 | 2013-10-17 | ||
GB201319828A GB201319828D0 (en) | 2013-11-11 | 2013-11-11 | Novel use |
GB1319828.8 | 2013-11-11 | ||
GB201409018A GB201409018D0 (en) | 2014-05-21 | 2014-05-21 | Novel use |
GB1409018.7 | 2014-05-21 | ||
PCT/EP2014/072074 WO2015055691A1 (en) | 2013-10-17 | 2014-10-15 | Pi3k inhibitor for treatment of respiratory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2016112266A true RU2016112266A (ru) | 2017-11-20 |
Family
ID=51842492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016112266A RU2016112266A (ru) | 2013-10-17 | 2014-10-15 | Ингибитор PI3K для лечения респираторного заболевания |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160263109A1 (ru) |
EP (1) | EP3057588A1 (ru) |
JP (1) | JP6475707B2 (ru) |
KR (1) | KR20160062178A (ru) |
CN (1) | CN105611929A (ru) |
AU (2) | AU2014336251A1 (ru) |
CA (1) | CA2925064A1 (ru) |
RU (1) | RU2016112266A (ru) |
WO (1) | WO2015055691A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201509492D0 (en) | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
CN111773219A (zh) * | 2020-08-11 | 2020-10-16 | 王思慧 | Pi3k抑制剂nvp-byl719在制备新型冠状病毒抑制剂中的应用 |
KR102672515B1 (ko) | 2022-04-07 | 2024-06-04 | 한양대학교 에리카산학협력단 | 레일 로봇 및 레일 로봇 시스템 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
EP1870122A3 (en) | 1995-04-14 | 2008-03-12 | SmithKline Beecham Corporation | Metered dose inhaler |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
EP1070056B1 (en) | 1998-03-14 | 2004-06-30 | ALTANA Pharma AG | Phthalazinone pde iii/iv inhibitors |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
WO2000066590A2 (en) | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
WO2002012265A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
WO2003082787A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
EP1532113B1 (en) | 2002-08-21 | 2008-08-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
PL375993A1 (en) | 2002-09-16 | 2005-12-12 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
TW200811171A (en) | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
WO2005090352A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
KR100867071B1 (ko) | 2004-10-19 | 2008-11-04 | 에프. 호프만-라 로슈 아게 | 퀴놀린 유도체 |
US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
GB0612630D0 (en) * | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
JO3025B1 (ar) * | 2009-04-30 | 2016-09-05 | Glaxo Group Ltd | الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3 |
DK2614058T3 (en) * | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
ES2602972T3 (es) * | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
GB201018124D0 (en) * | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
-
2014
- 2014-10-15 CN CN201480056821.5A patent/CN105611929A/zh active Pending
- 2014-10-15 US US15/028,973 patent/US20160263109A1/en not_active Abandoned
- 2014-10-15 EP EP14790537.6A patent/EP3057588A1/en not_active Withdrawn
- 2014-10-15 AU AU2014336251A patent/AU2014336251A1/en not_active Abandoned
- 2014-10-15 WO PCT/EP2014/072074 patent/WO2015055691A1/en active Application Filing
- 2014-10-15 RU RU2016112266A patent/RU2016112266A/ru not_active Application Discontinuation
- 2014-10-15 CA CA2925064A patent/CA2925064A1/en not_active Abandoned
- 2014-10-15 KR KR1020167012679A patent/KR20160062178A/ko not_active Application Discontinuation
- 2014-10-15 JP JP2016523933A patent/JP6475707B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-08 AU AU2017225139A patent/AU2017225139A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3057588A1 (en) | 2016-08-24 |
US20160263109A1 (en) | 2016-09-15 |
AU2014336251A1 (en) | 2016-04-14 |
KR20160062178A (ko) | 2016-06-01 |
CN105611929A (zh) | 2016-05-25 |
CA2925064A1 (en) | 2015-04-23 |
JP2016533367A (ja) | 2016-10-27 |
AU2017225139A1 (en) | 2017-10-05 |
WO2015055691A1 (en) | 2015-04-23 |
JP6475707B2 (ja) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
JP2016506960A5 (ru) | ||
HRP20182059T1 (hr) | Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja | |
JP2016532673A5 (ru) | ||
RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
JP2009515814A5 (ru) | ||
RU2008143457A (ru) | Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы | |
RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
JP2013519680A5 (ru) | ||
JP2005517006A5 (ru) | ||
RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
JP2015522589A5 (ru) | ||
RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
JP2016503785A5 (ru) | ||
RU2016112266A (ru) | Ингибитор PI3K для лечения респираторного заболевания | |
RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
JP2016540811A5 (ru) | ||
JP2015518048A5 (ru) | ||
RU2015137972A (ru) | Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1) | |
JP2016533367A5 (ru) | ||
RU2018127494A (ru) | Химические соединения в качестве ингибиторов киназной активности | |
JP2015509483A5 (ru) | ||
RU2015150614A (ru) | Новые 3, 4-дигидро-2н-изохинолин-1-оны и 2, 3-дигидро-изоиндол-1-оны | |
JP2012520899A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20171016 |